{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:51:54Z","timestamp":1779933114780,"version":"3.53.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The presence of the JAK2 V617F mutation is now part of clinical diagnostic algorithms, and JAK2 status is routinely assessed when BCR\/ABL\u2212 chronic myeloproliferative neoplasms (MPNs) are suspected. The aim of this study was to evaluate performance of 3 screening and 1 quantitative method for JAK2 V617F detection. For the study, 43 samples (27 bone marrow aspirates and 16 peripheral blood samples) were selected. The screening assays were the JAK2 Activating Mutation Assay (InVivoScribe, San Diego, CA), JAK2 MutaScreen kit (Ipsogen, Luminy Biotech, Marseille, France), and a home-brew melting curve analysis method. Ipsogen\u2019s JAK2 MutaQuant assay was used for quantification of mutant and wild-type alleles. The limit of detection was 1% for the kit-based screening methods and 10% for the melting curve method. The JAK2 MutaQuant assay demonstrated analytic sensitivity of 0.01%. All 4 methods detected cases of BCR\/ABL\u2212 MPNs and gave negative results with BCR\/ABL+ chronic myelogenous leukemia, multiple myeloma, myelodysplastic syndrome, and normal cases.<\/jats:p>","DOI":"10.1309\/ajcpfhuqz9agueka","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T19:43:36Z","timestamp":1256154216000},"page":"713-721","source":"Crossref","is-referenced-by-count":36,"title":["Clinical Performance of <i>JAK2<\/i> V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory"],"prefix":"10.1093","volume":"132","author":[{"given":"Milena","family":"Cankovic","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Whiteley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Hawley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Zarbo","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjay","family":"Chitale","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Henry Ford Hospital, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,11,1]]},"reference":[{"key":"2023011909295150000_b1-1320713","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"2023011909295150000_b2-1320713","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","article-title":"The chronic myeloproliferative disorders: clonality and clinical heterogeneity","volume":"41","author":"Spivak","year":"2004","journal-title":"Semin Hematol"},{"key":"2023011909295150000_b3-1320713","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"2023011909295150000_b4-1320713","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2023011909295150000_b5-1320713","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2023011909295150000_b6-1320713","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2023011909295150000_b7-1320713","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2023011909295150000_b8-1320713","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"2023011909295150000_b9-1320713","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"2023011909295150000_b10-1320713","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng"},{"key":"2023011909295150000_b11-1320713","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2796.2004.01357.x","article-title":"Trends in the incidence of chronic Philadelphia chromosome negative (Ph\u2013) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983\u20131989","volume":"256","author":"Johansson","year":"2004","journal-title":"J Intern Med"},{"key":"2023011909295150000_b12-1320713","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2141.2005.05682.x","article-title":"Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2 (V617F) in granulocytes","volume":"130","author":"Lasho","year":"2005","journal-title":"Br J Haematol"},{"key":"2023011909295150000_b13-1320713","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023011909295150000_b14-1320713","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.leu.2404069","article-title":"Detection of JAK2 V617F as a first diagnostic test for erythrocytosis","volume":"20","author":"James","year":"2006","journal-title":"Leukemia"},{"key":"2023011909295150000_b15-1320713","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617 mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"2023011909295150000_b16-1320713","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2353\/jmoldx.2007.060133","article-title":"Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"9","author":"Chen","year":"2007","journal-title":"J Mol Diagn"},{"key":"2023011909295150000_b17-1320713","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1309\/LW7Q3739RBRMBXXP","article-title":"Comparative evaluation of three JAK2V617F mutation detection methods","volume":"128","author":"Frantz","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"2023011909295150000_b18-1320713","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1309\/NXXTGRCXD0TMA3C2","article-title":"Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"125","author":"Greiner","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2023011909295150000_b19-1320713","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1309\/TK0XL917XK2VLRPQ","article-title":"Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis","volume":"125","author":"Murugesan","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2023011909295150000_b20-1320713","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kr\u00f6ger","year":"2007","journal-title":"Blood"},{"key":"2023011909295150000_b21-1320713","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","article-title":"The JAK2 V617F mutation is detectable at very low level in peripheral blood of healthy donors [letter]","volume":"20","author":"Sidon","year":"2006","journal-title":"Leukemia"},{"key":"2023011909295150000_b22-1320713","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","article-title":"JAK2\n            \u00a0V617F: prevalence in a large Chinese hospital population","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"},{"key":"2023011909295150000_b23-1320713","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","article-title":"Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha","volume":"107","author":"Jones","year":"2006","journal-title":"Blood"},{"key":"2023011909295150000_b24-1320713","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"2023011909295150000_b25-1320713","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannuchi","year":"2007","journal-title":"Leukemia"},{"key":"2023011909295150000_b26-1320713","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannuchi","year":"2007","journal-title":"Blood"},{"key":"2023011909295150000_b27-1320713","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2008.133","article-title":"Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders","volume":"22","author":"Walz","year":"2008","journal-title":"Leukemia"},{"key":"2023011909295150000_b28-1320713","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.med.59.061506.154159","article-title":"A role for JAK2 mutations in myeloproliferative diseases","volume":"59","author":"Morgan","year":"2008","journal-title":"Annu Rev Med"},{"key":"2023011909295150000_b29-1320713","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/132\/5\/713\/48768198\/ajcp_132_5_713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/132\/5\/713\/48768198\/ajcp_132_5_713.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T09:53:45Z","timestamp":1674122025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/132\/5\/713\/1766061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,1]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,11,1]]},"published-print":{"date-parts":[[2009,11,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpfhuqz9agueka","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,11,1]]},"published":{"date-parts":[[2009,11,1]]}}}